aldesleukin
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | PROLEUKIN | — | 1998-01-09 | fda.gov ↗ |
| Approved | US (FDA) | PROLEUKIN | — | 1992-05-05 | fda.gov ↗ |
Trials 435 · started per year
Also used as a comparator or background therapy in 300 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 09 trials | ||||||
| Phase 0 | NCT07700121 Background | Oct 2026 → Oct 2028 expected | metastatic melanoma | Abramson Cancer Center at Penn Medicine | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06318871 Background | Aug 2024 → Feb 2027 expected | MIT family translocation renal cell carcinoma, chromophobe renal cell carcinoma, urothelial carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT05831033 Background | May 2023 → Feb 2027 expected | cancer | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT05649618 Background | Dec 2022 → Mar 2024 | cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05648994 Background | Dec 2022 → Feb 2024 | cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
| Phase 0 | NCT05141474 Background | Oct 2021 → Jan 2027 expected | cancer, epithelial neoplasm | Vall d'Hebron Institute of Oncology | Recruiting | No outcome recorded |
| Phase 0 | NCT04209712 Background | Jan → Dec 2020 | acute myeloid leukemia | Shanghai iCELL Biotechnology Co., Ltd | Unknown | No outcome recorded |
| Phase 0 | NCT03526185 Background | Feb 2018 → Dec 2020 | metastatic melanoma | Yale University | Terminated | No outcome recorded |
| Phase 0 | NCT02652455 Background | Mar 2016 → Aug 2020 | cutaneous melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1113 trials | ||||||
| Phase 1 | NCT07225439 Background | Sep 2026 → Dec 2027 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, high grade B-cell lymphoma, mantle cell lymphoma +2 | Paolo Caimi, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06904066 Background | Jul 2026 → Apr 2029 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1 | NCT06677710 Background | Jun → Dec 2026 | primary progressive multiple sclerosis, secondary progressive multiple sclerosis | Indapta Therapeutics, INC. | Suspended | No outcome recorded |
| Phase 1 | NCT07183852 Background | Mar 2026 → Mar 2028 expected | cutaneous melanoma, uveal melanoma | Vastra Gotaland Region | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07192900 Background | Mar 2026 → Dec 2032 expected | malignant mesothelioma, pleural neoplasm | David Bartlett, MD | Recruiting | No outcome recorded |
| Show all 113 trials opens the full record — a long page | ||||||
| Phase 1/278 trials | ||||||
| Phase 1/2 | NCT07651319 Comparator | Jul 2026 → Jun 2029 expected | Alzheimer disease | The Methodist Hospital Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07389239 Background | Jun 2026 → Dec 2031 expected | ovarian cancer | University of Chicago | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07591649 Background | May 2026 → Mar 2030 expected | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07510828 Background | Mar 2026 → Mar 2027 expected | — | Beijing Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07410494 Background | Feb 2026 → Dec 2027 expected | acute myeloid leukemia, breast cancer, colorectal cancer, cutaneous melanoma +7 | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06961357 Background | Dec 2025 → May 2029 expected | melanoma | H. Lee Moffitt Cancer Center and Research Institute | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07255664 Background | Nov 2025 → Apr 2027 expected | colorectal cancer, prostate cancer | CuraCell TX AB | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05639972 Background | Aug 2025 → Oct 2026 expected | adenosquamous carcinoma, anal squamous cell carcinoma, endocervical adenocarcinoma, human papillomavirus-related penile squamous cell carcinoma +3 | Christian Hinrichs | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06598371 Background | Nov 2024 → Aug 2039 expected | neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06158828 Background | Nov 2024 → Sep 2028 expected | acute myeloid leukemia by FAB classification, childhood acute myeloid leukemia | Washington University School of Medicine | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06640582 Background | Oct 2024 → Sep 2026 expected | glioblastoma, meningioma, metastatic malignant neoplasm in the brain, primary brain neoplasm | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06532799 Background | Sep 2024 → Dec 2025 overdue | esophageal cancer, gastric adenocarcinoma | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06532812 Background | Aug 2024 → Dec 2025 overdue | triple-negative breast carcinoma | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06538012 Background | Aug 2024 → Sep 2026 expected | non-small cell lung carcinoma | Essen Biotech | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06237881 Background | Jan 2024 → Jan 2027 expected | head and neck neoplasm, lung neoplasm, melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05981001 Background | Aug 2023 → Apr 2032 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05981014 Background | Aug 2023 → Dec 2030 expected | breast neoplasm | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05566223 Background | Feb 2023 → Nov 2025 | large cell carcinoma, lung adenocarcinoma, squamous cell lung carcinoma | Intima Bioscience, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05357027 Background | Aug 2022 → Jan 2026 | cervical carcinoma | TCRCure Biopharma Ltd. | Terminated | No outcome recorded |
| Phase 1/2 | NCT05194735 Background | Apr 2022 → Aug 2023 | adenosquamous lung carcinoma, cholangiocarcinoma, colorectal cancer, endometrial cancer +3 | Alaunos Therapeutics | Terminated | No outcome recorded |
| Phase 1/2 | NCT05296564 Background | Apr 2022 → Dec 2027 expected | metastatic malignant neoplasm, metastatic melanoma, neuroblastoma, non-small cell lung carcinoma +4 | Hadassah Medical Organization | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05218408 Background | Sep → Oct 2021 | giant cell glioblastoma | Celularity Incorporated | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04673617 Background | Mar 2021 → Oct 2025 | B-cell non-Hodgkin lymphoma | Artiva Biotherapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04347616 Comparator | Dec 2020 → Jan 2026 | acute myeloid leukemia | Radboud University Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04729543 Background | Oct 2020 → Dec 2024 overdue | uveal melanoma | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04389229 Background | Jul 2020 → Mar 2023 | ovarian cancer | Immetacyte Ltd | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT04426669 Background | May 2020 → May 2025 | colorectal cancer, esophageal cancer, gallbladder cancer, gastric cancer +1 | Intima Bioscience, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03658785 Background | Apr 2020 → Dec 2024 overdue | metachronous kidney Wilms' tumor, metastatic malignant neoplasm | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03745326 Background | May 2019 → Aug 2022 | colon carcinoma, gastric cancer, malignant pancreatic neoplasm, rectal cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT03778619 Background | Nov 2018 → Apr 2020 | non-Hodgkin lymphoma | GC Cell Corporation | Unknown | No outcome recorded |
| Phase 1/2 | NCT03318900 Background | Sep 2018 → Dec 2023 | ovarian carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03374839 Background | Feb 2018 → Jan 2024 | melanoma | Nantes University Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT03098355 Background | Dec 2017 → Dec 2022 | B-cell acute lymphoblastic leukemia | Zhujiang Hospital | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02770820 Background | Nov 2017 → Jun 2020 | Epstein-Barr virus-related tumor, acute myeloid leukemia | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT03296137 Background | Oct 2017 → Mar 2020 | cancer | Inge Marie Svane | Completed | No outcome recorded |
| Phase 1/2 | NCT03287674 Background | Oct 2017 → Jun 2020 | ovarian cancer | Inge Marie Svane | Completed | No outcome recorded |
| Phase 1/2 | NCT03242603 Background | Oct 2017 → Aug 2019 | neuroblastoma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT03190941 Background | Sep 2017 → Jun 2027 expected | colon carcinoma, gastric cancer, malignant pancreatic neoplasm, rectal cancer | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03171220 Background | Jun 2017 → Dec 2019 | cancer | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
| Phase 1/2 | NCT03044743 Background | Apr 2017 → Mar 2020 | Hodgkins lymphoma, T-cell non-Hodgkin lymphoma, diffuse large B-cell lymphoma, gastric carcinoma +1 | Yang Yang | Unknown | No outcome recorded |
| Phase 1/2 | NCT02830724 Background | Apr 2017 → Jan 2029 expected | breast cancer, malignant pancreatic neoplasm, melanoma, ovarian cancer +1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT02858310 Background | Jan 2017 → Jul 2025 | cervical intraepithelial neoplasia, human papilloma virus infection, in situ carcinoma, vulvar neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02620865 Background | Dec 2015 → Jun 2021 | pancreatic adenocarcinoma | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT02408016 Background | May 2015 → Jun 2020 | malignant pleural mesothelioma, non-small cell lung carcinoma | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02414945 Background | May 2015 → Oct 2020 | malignant pleural mesothelioma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1/2 | NCT02390739 Background | Mar 2015 → Mar 2017 | thyroid cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02409576 Background | Feb 2015 → Aug 2020 | Ewing sarcoma, rhabdomyosarcoma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT02315118 Background | Dec 2014 → Dec 2017 | B-cell chronic lymphocytic leukemia | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 1/2 | NCT02354690 Background | Nov 2014 → Dec 2018 | metastatic melanoma | Inge Marie Svane | Completed | No outcome recorded |
| Phase 1/2 | NCT02173093 Background | Nov 2014 → Dec 2019 | neuroblastoma | University of Virginia | Unknown | No outcome recorded |
| Phase 1/2 | NCT02379195 Background | Nov 2014 → Jan 2018 | metastatic melanoma | Inge Marie Svane | Completed | No outcome recorded |
| Phase 1/2 | NCT02280811 Background | Oct 2014 → Jun 2016 | anus cancer, cervical cancer, oropharynx cancer, penile cancer +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01898793 Background | Aug 2014 → Dec 2021 | acute myeloid leukemia | Washington University School of Medicine | Terminated | No outcome recorded |
| Phase 1/2 | NCT02153905 Background | Jul 2014 → Sep 2018 | breast cancer, cervical cancer, kidney cancer, melanoma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT02111850 Background | Feb 2014 → Mar 2021 | breast cancer, cervical cancer, kidney cancer, melanoma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01823198 Background | Jun 2013 → May 2022 | acute erythroid leukemia, acute megakaryoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, chronic myelomonocytic leukemia +2 | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01640301 Background | Dec 2012 → Mar 2020 | MHC class I deficiency 2, childhood acute myeloid leukemia, disease related to hematopoietic stem cell transplant, therapy related acute myeloid leukemia and myelodysplastic syndrome | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT01592045 Background | Aug 2012 → Jun 2014 | neuroblastoma | United Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT01454596 Background | May 2012 → Nov 2018 | gliosarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01583686 Background | May 2012 → Dec 2018 | cervical cancer, lung cancer, malignant pancreatic neoplasm, mesothelioma +1 | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT01550367 Background | Mar 2012 → Feb 2018 | renal cell carcinoma | Leonard Appleman | Completed | No outcome recorded |
| Phase 1/2 | NCT01235845 Background | Jan 2011 → Dec 2012 | malignant glioma | Qingdao University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01273181 Background | Dec 2010 → Dec 2012 | metastatic malignant neoplasm, metastatic melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT01081223 Background | Apr 2010 → Mar 2011 | glioblastoma | TVAX Biomedical | Completed | No outcome recorded |
| Phase 1/2 | NCT00862303 Comparator | Mar 2009 → Jun 2015 | renal cell carcinoma | Fuzhou General Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT00924326 Background | Feb 2009 → Sep 2015 | mantle cell lymphoma, primary mediastinal large B-cell lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00871481 Background | Feb 2009 → Sep 2013 | melanoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00553306 Background | Sep 2007 → Aug 2010 | metastatic melanoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00924001 Background | Aug 2007 → Oct 2010 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00303667 Background | Jan 2005 → Mar 2011 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1/2 | NCT00197912 Background | Sep 2004 → Apr 2010 | melanoma | Herlev Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT00197860 Background | Sep 2004 → Dec 2009 | renal cell carcinoma | Inge Marie Svane | Completed | No outcome recorded |
| Phase 1/2 | NCT00058279 Background | Feb 2003 → Aug 2006 | cutaneous melanoma, ocular melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/2 | NCT00052520 Background | Sep 2002 → Apr 2011 | B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia +11 | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT06152367 Background | Jan 2001 → Oct 2004 | cutaneous melanoma | University of Chile | Completed | No outcome recorded |
| Phase 1/2 | NCT00277017 Background | Sep 2000 → Aug 2005 | cancer, kidney disorder | New Mexico Cancer Research Alliance | Completed | No outcome recorded |
| Phase 1/2 | NCT00003229 Background | Jul 1997 → Apr 2000 | cutaneous melanoma | Duke University | Completed | No outcome recorded |
| Phase 1/2 | NCT00002786 Background | Oct 1995 → Mar 2006 | cutaneous melanoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 286 trials | ||||||
| Phase 2 | NCT07651618 Background | Jul 2026 → Jul 2029 expected | cutaneous melanoma, metastatic melanoma | East Metropolitan Health Service, Australia | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07646639 Background | May 2026 → Dec 2028 expected | rectal cancer | The First Affiliated Hospital with Nanjing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07406724 Background | Feb 2026 → Dec 2027 expected | melanoma | Qingdao Sino-Cell Biomedicine Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07288073 Background | Feb 2026 → Sep 2028 expected | cutaneous neuroendocrine carcinoma, skin squamous cell carcinoma | Karam Khaddour, MD, MS | Recruiting | No outcome recorded |
| Phase 2 | NCT06690281 Background | Sep 2025 | cholangiocarcinoma, colorectal cancer, duodenum cancer, hepatocellular carcinoma +2 | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT06630611 Comparator | Jan 2025 → Sep 2029 expected | cervical cancer, melanoma, non-small cell lung carcinoma | Vall d'Hebron Institute of Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT04102436 Background | Mar 2024 | breast cancer, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT06151847 Background | Dec 2023 → Jul 2025 | cutaneous melanoma, metastatic melanoma | University of Kansas Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05883449 Background | Oct 2023 → Nov 2024 | Hodgkins lymphoma, peripheral T-cell lymphoma, not otherwise specified | Affimed GmbH | Terminated | No outcome recorded |
| Phase 2 | NCT04354025 Background | Jun 2023 → Sep 2026 | acute myeloid leukemia | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT06047860 Background | Jun 2023 → Dec 2024 | refractory malignant neoplasm | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT05686226 Background | Mar 2023 → Jan 2027 expected | adenosquamous carcinoma, anal squamous cell carcinoma, endocervical adenocarcinoma, human papillomavirus-related penile squamous cell carcinoma +4 | Christian Hinrichs | Recruiting | No outcome recorded |
| Phase 2 | NCT04893915 Background | Jun 2022 → Dec 2024 | acute myeloid leukemia, myelodysplastic syndrome | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 2 | NCT06096090 Comparator | Jan 2022 → Dec 2025 | Alzheimer disease | The Methodist Hospital Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT05115500 Background | Nov 2021 → Oct 2024 | carcinoma | Second Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 2 | NCT04536922 Background | Jan 2021 | anal squamous cell carcinoma | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 2 | NCT04241601 Comparator | Aug 2020 → Jan 2023 | acute coronary syndrome | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT04166006 Background | Dec 2019 → Apr 2027 expected | head and neck neoplasm, neuroendocrine neoplasm, soft tissue sarcoma | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting | No outcome recorded |
| Phase 2 | NCT04077684 Comparator | Sep 2019 → Mar 2024 | systemic lupus erythematosus | Peking University People's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03935347 Background | Jun 2019 → May 2022 | bladder transitional cell carcinoma, renal pelvis urothelial carcinoma, ureter transitional cell carcinoma, urethra transitional cell carcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT03801083 Background | Feb 2019 → Jan 2030 expected | cholangiocarcinoma | Udai Kammula | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03610490 Background | Oct 2018 → Aug 2024 | colorectal adenocarcinoma, ovarian carcinosarcoma, ovarian serous adenocarcinoma, pancreatic ductal adenocarcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT03412877 Background | Sep 2018 → Mar 2028 expected | breast cancer, neuroendocrine neoplasm, non-small cell lung carcinoma, ovarian cancer +1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT03501381 Background | May 2018 → Jan 2023 overdue | renal cell carcinoma | Roberto Pili | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03467516 Background | May 2018 → Jul 2027 expected | uveal melanoma | Udai Kammula | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03449108 Background | Apr 2018 → Apr 2027 expected | bone giant cell tumor, dedifferentiated chondrosarcoma, malignancy in giant cell tumor of bone, osteosarcoma +7 | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04011033 Background | Mar 2018 → Mar 2020 | hepatocellular carcinoma | Beijing YouAn Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03412526 Background | Jan 2018 → Feb 2021 | ovarian cancer | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03166397 Background | Jun 2017 → Jan 2025 | metastatic melanoma | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02919644 Background | Dec 2016 → Dec 2026 expected | colorectal cancer | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Recruiting | No outcome recorded |
| Phase 2 | NCT02763475 Background | May 2016 → Aug 2020 | acute myeloid leukemia | Instituto de Investigación Hospital Universitario La Paz | Completed | No outcome recorded |
| Phase 2 | NCT02621021 Background | Dec 2015 → Jun 2028 expected | melanoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT02641782 Comparator | Nov 2015 → Dec 2016 | neuroblastoma | University of Cologne | Terminated | No outcome recorded |
| Phase 2 | NCT02259348 Background | Oct 2014 → Apr 2015 | acute lymphoblastic leukemia, chronic myeloid leukemia, juvenile myelomonocytic leukemia, myelodysplastic syndrome +1 | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01795976 Background | Oct 2014 → Nov 2017 | esophageal cancer | Fiona Thistlethwaite | Terminated | No outcome recorded |
| Phase 2 | NCT01995344 Comparator | Mar 2014 → Jul 2015 | metastatic melanoma | The Christie NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 2 | NCT02111863 Background | Feb 2014 → Jul 2016 | melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT02062359 Background | Feb 2014 → Feb 2016 | metastatic malignant neoplasm, metastatic melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01993719 Background | Dec 2013 → Oct 2021 | metastatic melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01967823 Background | Oct 2013 → Apr 2020 | breast cancer, hepatocellular carcinoma, melanoma, meningioma +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01639456 Background | Oct 2013 → Jan 2017 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Withdrawn | No outcome recorded |
| Phase 2 | NCT01807182 Background | Aug 2013 → Aug 2021 | cutaneous melanoma, metastatic melanoma | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01857934 Background | Jul 2013 → Oct 2021 | neuroblastoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01700946 Comparator | Apr 2013 → Jul 2021 | B-cell childhood acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01884688 Background | Apr 2013 → Oct 2016 | plasma cell myeloma | University of Arkansas | Completed | No outcome recorded |
| Phase 2 | NCT01593670 Background | Mar 2013 → Oct 2018 | myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01697527 Background | Nov 2012 → Nov 2026 expected | cancer | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01585428 Background | Apr 2012 → Apr 2016 | anus cancer, cervical cancer, oropharyngeal carcinoma, penile cancer +1 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01390402 Background | Jan 2012 → Nov 2014 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01370213 Background | Sep 2011 → Apr 2016 | acute myeloid leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01416831 Comparator | Jul 2011 → Apr 2017 overdue | metastatic melanoma | Providence Health & Services | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01369875 Background | Jun 2011 → Feb 2012 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT01319565 Background | Mar 2011 → Sep 2024 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01174121 Background | Aug 2010 → Dec 2028 expected | breast carcinoma, colorectal cancer, malignant pancreatic neoplasm, neuroendocrine neoplasm +1 | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT01181258 Background | Aug 2010 → Sep 2015 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT01106950 Background | Jul 2010 → Oct 2011 | acute myeloid leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00910650 Background | Oct 2009 → May 2019 | metastatic melanoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01274273 Comparator | Oct 2009 → Dec 2015 | renal cell carcinoma | University of Aarhus | Unknown | No outcome recorded |
| Phase 2 | NCT00935558 Background | Jul 2009 → May 2012 | breast cancer | Inge Marie Svane | Withdrawn | No outcome recorded |
| Phase 2 | NCT00923195 Background | Dec 2008 → Aug 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00652899 Background | Mar 2008 → Aug 2009 | fallopian tube cancer, ovarian cancer, peritoneum cancer | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00610311 Background | Jan 2008 → Feb 2011 | metastatic melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00509496 Background | Jun 2007 → Jul 2011 | melanoma, skin cancer | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00513604 Background | Jun 2007 → Nov 2012 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00485563 Background | Jun 2007 → Aug 2008 | renal cell carcinoma | Endocyte | Terminated | No outcome recorded |
| Phase 2 | NCT00393029 Background | Oct 2006 → Nov 2008 | — | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00376805 Background | Apr 2006 → Sep 2009 | breast cancer | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00338377 Background | Feb 2006 → Feb 2030 expected | melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00354172 Background | Feb 2006 → Aug 2008 | leukemia, myelodysplastic syndrome | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00325507 Background | Nov 2005 → Jul 2008 | renal cell carcinoma | Oxford BioMedica | Completed | No outcome recorded |
| Phase 2 | NCT00274846 Background | Mar 2005 → Jun 2008 | leukemia | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 2 | NCT00083941 Background | Aug 2004 → Jul 2008 | renal cell carcinoma | Oxford BioMedica | Completed | No outcome recorded |
| Phase 2 | NCT00100906 Comparator | Aug 2004 → Jun 2006 | kidney cancer | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00101101 Background | Jul 2004 → Oct 2012 | lymphoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00071890 Comparator | Oct 2003 → Dec 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 2 | NCT00072085 Background | Sep 2003 → Jul 2006 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00032188 Background | Jan 2002 → Jun 2006 | renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00020397 Background | Nov 2000 → Jul 2005 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00176761 Background | Mar 2000 → May 2006 | colorectal cancer | University of Michigan Rogel Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00928902 Comparator | Nov 1999 → Apr 2001 | melanoma | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00019994 Background | Oct 1999 → Oct 2007 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00001827 Background | Jul 1999 → Dec 2007 | ovarian neoplasm | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00005038 Background | Jun 1999 → ? | renal cell carcinoma | The Christie NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 2 | NCT00331526 Background | Feb 1999 → Dec 2008 | central nervous system neoplasm | Hoag Memorial Hospital Presbyterian | Completed | No outcome recorded |
| Phase 2 | NCT00003222 Background | Apr 1998 → Sep 2003 | cutaneous melanoma | University of Virginia | Completed | No outcome recorded |
| Phase 2 | NCT00002589 Background | Jul 1994 → ? | renal cell carcinoma | National Cancer Institute (NCI) | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT02278887 Background | Sep 2014 → Sep 2022 | metastatic melanoma | The Netherlands Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00397345 Background | Sep 2006 → Dec 2009 | clear cell renal carcinoma | Oxford BioMedica | Completed | No outcome recorded |
| Phase 3 | NCT00149162 Comparator | Mar 2005 → Dec 2010 | leukemia | Assistance Publique - Hôpitaux de Paris | Unknown | No outcome recorded |
| Phase 3 | NCT00311467 Comparator | Mar 2004 → May 2007 | renal cell carcinoma | Central European Cooperative Oncology Group | Terminated | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01856023 Comparator | May 2013 → Jul 2015 | metastatic melanoma | Clinigen, Inc. | Terminated | No outcome recorded |
| Phase 4 | NCT00352885 Background | Oct 2006 → May 2010 | depressive disorder | Emory University | Completed | No outcome recorded |
| Phase not applicable7 trials | ||||||
| — | NCT06256627 Comparator | Jul 2023 → Mar 2025 overdue | acute myeloid leukemia | Henan Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT03101423 Comparator | Aug 2016 → Dec 2019 | beta-thalassemia major | First Affiliated Hospital of Guangxi Medical University | Unknown | No outcome recorded |
| — | NCT01701674 Background | Oct 2012 → Apr 2016 | metastatic melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| — | NCT01005745 Background | Oct 2009 → Jan 2014 | metastatic melanoma | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| — | NCT00187096 Background | Sep 2005 → Feb 2012 | acute myeloid leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| — | NCT00912418 Background | May 2000 → Sep 2002 | melanoma | Craig L Slingluff, Jr | Completed | No outcome recorded |
| — | NCT00000875 Background | ? → Apr 2003 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT04135092 Background | — | — | National Institutes of Health Clinical Center (CC) | No longer available | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-04-09 | Sanofi | Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2 sanofi.com ↗ |
Evidence & citations 40 cited values
Every value below carries the sentence it was read from. 757 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aldesleukin | “Temozolamide 150mg/m2 x4, cisplatin 20mg/m2 x 4, vinblastine 1.2mg/m2 x 4, bevacizumab 7.5-15 mg/kg x 1, interferon 5mg/m2 x5 and aldesleukin 36,18,9, % 9 miu/day over 4 days...” NCT01743157 ↗361“Folowed by Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period approximately every 8 hours...” NCT03467516 ↗ “This study will evaluate whether the HIV vaccine ALVAC vCP1452 given in combination with interleukin-2 (IL-2), also known as aldesleukin, can increase immune system function in...” NCT00056797 ↗ “This study focuses on combining TIL therapy with Pembrolizumab (Keytruda) and Aldesleukin (IL-2) to enhance the anti-tumor immune response in patients with advanced or...” NCT06532812 ↗ “PURPOSE: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR)...” PMID 25424850 ↗ Nov 2014 “The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in...” NCT00110812 ↗ “Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.” NCT01081808 ↗ “IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.” NCT02739412 ↗ “called IL-2 (Aldesleukin), which will be given as an every-other-day injection under the skin (subcutaneous) at very low doses for 6 weeks after the ASCT” NCT02676622 ↗ “Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days” NCT01289678 ↗ “A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma” NCT01683188 ↗ “Patients were randomised (1:1:1) to aldesleukin 2 MIU, 1 MIU, or placebo once daily for 5 days every 4 weeks for 3 cycles.” PMID 32651161 ↗ Jul 2020 “recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:” NCT01840046 ↗ “8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab” NCT00100737 ↗ “Aldesleukin, administered at a dose of 600,000 IU/kg (based on total body weight) as an intravenous bolus” NCT03801083 ↗ “Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity” NCT06318871 ↗ “Interleukin 2 (IL-2, aldesleukin) was discovered as a T cell growth factor more than 30 years ago.” NCT01445561 ↗ “Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells” NCT06096090 ↗ “Aldesleukin may stimulate the lymphocytes to kill tumor cells.” NCT00863330 ↗ “Aldesleukin (IL-2) is given to stimulate the TILs' activity.” NCT06532799 ↗ “Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).” NCT04263831 ↗ “Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).” NCT02200445 ↗ “followed by the administration of aldesleukin (IL-2).” NCT03526185 ↗ “recombinant interleukin-2 (Proleukin, Aldesleukin)” NCT00040586 ↗ “Aldesleukin (interleukin-2, IL-2) immunotherapy” NCT06530303 ↗ “human recombinant IL-2 (aldesleukin; Novartis)” NCT01324960 ↗ “High Dose Aldesleukin (Interleukin-2)” NCT01856023 ↗ “Interleukin-2 (Aldesleukin)” NCT07610538 ↗ “ILT-101 (Aldesleukin; IL-2)” NCT03243058 ↗ “Interleukin-2 (aldesleukin)” NCT00910650 ↗ “Aldesleukin (IL2), 3x10 IU” NCT01884688 ↗ “Drug: Aldesleukin” NCT02153905 ↗ “Drug: Aldesleukin” NCT02390739 ↗ |
| Known as | Aldesleukin, Proleukin, IL-2 | “Aldesleukin, Proleukin, IL-2” NCT06152809 ↗ |
| Known as | HD IL2 | “To assess the combination of high dose interleukin 2 (HD IL2) and nivolumab in patients with checkpoint inhibitor-refractory melanoma or renal cell carcinoma (RCC), we...” PMID 42070986 ↗ Apr 20263“PURPOSE: High-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR)...” PMID 25424850 ↗ Nov 2014 “High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)” NCT04562129 ↗ |
| Known as | High Dose Interleukin-2 | “High Dose Interleukin-2” NCT02989714 ↗ |
| Known as | High-Dose IL-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03226236 ↗ |
| Known as | hIL-2 | “subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).” NCT00224354 ↗ |
| Known as | HrIL-2 | “Patients receive low dose recombinant human Interleukin-2（HrIL-2）” NCT02084238 ↗1“Patients receive low dose recombinant human Interleukin-2（HrIL-2）” NCT02932137 ↗ |
| Known as | Human recombinant IL-2 = Aldesleukin (Novartis) | “Human recombinant IL-2 = Aldesleukin® (Novartis)” NCT01324960 ↗ |
| Known as | human recombinant interleukin 2 | “supplemental human recombinant interleukin 2 (IL-2)” NCT05336409 ↗ |
| Known as | IL-2 | “This study is designed as a randomized, open trial of intermittent continuous infusions of Interleukin-2 in HIV seropositive patients with a CD4 cell count between 200 and 500...” NCT00001474 ↗229“This investigation is a sub-study of the 6-year multinational ESPRIT (Evaluation of Subcutaneous Proleukin in a Randomized International Trial) protocol. It will compare the...” NCT00050726 ↗ “This study is for patients with advanced stage III or stage IV melanoma not adequately treated by surgery who have progressed after treatment with nivolumab or pembrolizumab....” NCT02796352 ↗ “The investigators hypothesize that ex vivo expanded human autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cells (Polyclonal Tregs) plus Interleukin-2 (IL-2) administered...” NCT02772679 ↗ “We propose a dose finding study of escalating low doses of IL 2 (subcutaneous), since no prior study has specifically evaluated the use of low dose IL-2 as a cytokine adjuvant...” NCT00203866 ↗ “This study will assess the highest tolerable intratumoral dose of ipilimumab (Yervoy) in combination with IL-2 (Proleukin) in patients with unresectable stages III-IV melanoma...” NCT01672450 ↗ “This study will evaluate the long-term toxicity and obtain preliminary information about long-term efficacy of the combination of antiretroviral therapies and interleukin-2...” NCT00001282 ↗ “To evaluate the short-term effects of administering zidovudine ( AZT ) at the same time with increasing doses of aldesleukin ( interleukin-2; IL-2 ) in patients with persistent...” NCT00000728 ↗ “Beginning 6 hours after TIL infusion, patients receive high-dose aldesleukin (IL-2) IV three times daily on days 0-5 (for up to 14 doses) OR low-dose IL-2 subcutaneously twice...” NCT01005537 ↗ “AIMS/HYPOTHESIS: Low-dose IL-2 (ld-IL2) selectively activates and expands regulatory T cells (Tregs) and thus has the potential to skew the regulatory/effector T (Treg/Teff)...” PMID 32607749 ↗ Jul 2020 “These cells kill tumor cells in a non-MHC restricted manner, do not induce graft-versus-host disease (GVHD), and can be generated by stimulation with zoledronic acid (ZA) in...” PMID 38165016 ↗ Jan 2024 “Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV...” NCT00604136 ↗ “Determine the safety of peripheral blood lymphocytes (PBLs) retrovirally transduced with an anti-MART-1 T-cell receptor (TCR) gene followed by high-dose aldesleukin (IL-2) and...” NCT00091104 ↗ “This study will evaluate whether the HIV vaccine ALVAC vCP1452 given in combination with interleukin-2 (IL-2), also known as aldesleukin, can increase immune system function in...” NCT00056797 ↗ “Each patients will receive four cycles of subcutaneous Proleukin (Interleukin-2, IL-2) (Week-1; 1.5 million IU (MIU)/d from Day-1 to Day-5, Week-3, -6, -9; 3MIU/d from Day-1 to...” NCT02714959 ↗ “Dacarbazine (DTIC) and a low-dose of Proleukin (IL2), would provide a less toxic and more effective treatment for melanoma than currently available treatments for people with...” NCT00553618 ↗ “Patients receive anti-MART-1 F5 TCR-transduced PBLs as in arm I and aldesleukin SC on days 0-4. 1 x 10e9 to 5 x 10e10 IV + IL-2 (based on body weight) 125,000 IU/kg/day subcutaneously.” NCT00706992 ↗ “We randomly assigned 100 patients in a 1:1 ratio to receive either 1.5 million IU/day of subcutaneous IL-2 (ILT-101) or placebo for 5 days followed by weekly injections for 12 weeks.” PMID 35973803 ↗ Aug 2022 “the impact of the immune-modulating drugs zoledronic acid (ZA) and interleukin-2 (IL-2) as co-treatment with zolbetuximab on relevant immune cell populations and ADCC lysis activity.” PMID 36607429 ↗ Jan 2023 “In this study, we evaluated the safety and efficacy of two dosing frequencies of low-dose Interleukin-2 (IL-2) in expanding Tregs to modify disease progression in AD individuals.” PMID 40615880 ↗ Jul 2025 “IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.” NCT02739412 ↗ “Intravenous infusion of NEUKIO203-13 d1,d4,d7 and IL-2 6 mIU d1,d4,d7 and d10 was administered following lymphodepletion with cyclophosphamide combined with fludarabine.” NCT07366658 ↗ “Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m\^2/day for the first week and at a dose of 4.5 MIU/m\^2/day for the second week during Courses 2 and 4.” NCT01592045 ↗ “Interleukin-2 (IL-2) increases the number of CD4 cells in HIV-1 infected patients under highly active antiretroviral therapy (HAART) with a CD4 cell count over 200/mm3” NCT00120185 ↗ “Administration of interleukin-2 (also known as aldesleukin or IL-2), a naturally occurring cytokine, has been proposed as a way to maintain the number of CD8 cells.” NCT00110578 ↗ “two cytokine treatments, Interleukin-2 (IL2) and/or alpha interferon (IFN), for patients with intermediate chance of response in metastatic renal cell carcinoma.” NCT00291369 ↗ “IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.” NCT05385705 ↗ “Optional cytokine support (e.g., low-dose IL-2) may be used per protocol to support NK persistence, consistent with approaches used in some CAR-NK studies.” NCT07410494 ↗ “The aim of this study was to assess efficacy and safety of adjuvant treatment with low doses of interleukin-2 (IL-2)+interferon-α (IFN-α) in operable RCC.” PMID 25304727 ↗ Nov 2014 “called IL-2 (Aldesleukin), which will be given as an every-other-day injection under the skin (subcutaneous) at very low doses for 6 weeks after the ASCT” NCT02676622 ↗ “Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days” NCT01289678 ↗ “Eligible subjects will receive injection of C-TIL052A (Autologous Tumor Infiltrating Lymphocytes, TIL) and interleukin 2 (IL-2) after lymphodepletion.” NCT05475847 ↗ “This study examines the long-term effects of interleukin-2 (IL-2) in combination with anti-HIV drugs, or highly active antiretroviral therapy (HAART).” NCT00000923 ↗ “Recombinant IL-2 will be given subcutaneously at a dose of 3 MUI twice daily for 5 days every 8 weeks for 5 cycles from week 14 to week 46.” NCT00196586 ↗ “Insulin antigen injected directly into inguinal lymph node; 3 injections at monthly intervals (Months 2-4) combined with low-dose IL-2” NCT07610213 ↗ “DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations.” NCT01235845 ↗ “After TIL infusion, IL-2 (optional) will be started as a bolus administration every eight hours, for a maximum of fourteen doses.” NCT04643574 ↗ “The purpose of this paper is to explore the effect of low-dose IL-2 on refractory dermatomyositis and immunological indexes.” NCT05495321 ↗ “Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2.” NCT01586403 ↗ “Drug: IL-2 After 18-24 hours of infusion of YK0901 cells, the patients will be given a small dose of IL-2 subcutaneously” NCT05933668 ↗ “Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer” NCT02306954 ↗ “During the last 8 weeks of HAART (until W44), patients received daily sc low-dose interleukin-2 (IL-2)(0.75 MU/kg QD).” NCT00979706 ↗ “Together with high-dose interleukin (IL)-2 this treatment has been given to patients with advanced malignant melanoma” PMID 22909342 ↗ Aug 2012 “Eighteen patients with metastatic renal cell carcinoma were treated with ATRA followed by s.c. interleukin 2 (IL-2).” PMID 16982775 ↗ Sep 2006 “IL-2 2 MIU s.c. day 2-6 and Thymosin alpha 1 (Zadaxin®, SciClone) 1,6 mg s.c. twice a week are used for adjuvants.” NCT00197860 ↗ “Lymphodepleting Chemotherapy with Fludarabine/Cyclophosphamide followed by TIL and Post-TIL Interleukin-2 (IL-2)” NCT06047977 ↗ “8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab” NCT00100737 ↗ “IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.” NCT03242603 ↗ “Interleukin-2 (aldesleukin, IL-2) will be used to support natural killer cell proliferation and activity” NCT06318871 ↗ “Patients received daily subcutaneous interleukin-2 (IL-2, 2 MIU) up to 14 days after TIL administration.” PMID 41850738 ↗ Mar 2026 “IL-2：Administer 8-16 hr after TIL infusion. 600,000 IU/kg intravenously over 15-20 mins every 12 hours.” NCT05831033 ↗ “Interleukin 2 (IL-2, aldesleukin) was discovered as a T cell growth factor more than 30 years ago.” NCT01445561 ↗ “Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system.” NCT01659151 ↗ “Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system.” NCT03215810 ↗ “Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients” NCT00000821 ↗ “Analyzing the effect of "IFN-α- 1b, il-2, and thalidomide" on negative conversion rate of MRD .” NCT06256627 ↗ “Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks.” NCT00697671 ↗ “subcutaneous interleukin-2 (aldesleukin; IL-2) in patients with myelodysplastic syndrome (MDS)” NCT00002746 ↗ “comprising interleukin-2 (IL-2) IV continuously over days 1-5, 15-19, 43-47, and 57-61” NCT00416871 ↗ “IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system)” NCT00006291 ↗ “Concomitantly the patients were treated with IL-2, Cyclophosphamide, and Celecoxib.” PMID 22426890 ↗ Mar 2012 “Each pateint will receive IL-2 to support NK cell activation and expansion in vivo” NCT02409576 ↗ “low-dose subcutaneous IL-2 (125,000 IU/kg/day, maximum 9-10 doses over 2 weeks)” PMID 30747243 ↗ Feb 2019 “4 hours after NK cells infusion，IL-2 is applied every other day for six times” NCT03619954 ↗ “Participants will also get aldesleukin (IL-2) to help the cells last longer.” NCT03197025 ↗ “Drug: IL-2 Following cell infusion, the patient receives intravenous IL-2.” NCT05868915 ↗ “Patients will receive low dose IL-2 after infusion of activated NK cells.” NCT00717184 ↗ “continuous infusion outpatient interleukin 2 (IL2) for two weeks” NCT00673829 ↗ “IL-2 is designed to help NK cells live longer and work better.” NCT00941928 ↗ “Drug: Proleukin 600.000 IU/kg/dose IL-2 a maximum of 6 doses” NCT06204991 ↗ “Aldesleukin (IL-2) is given to stimulate the TILs' activity.” NCT06532799 ↗ “Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).” NCT04263831 ↗ “Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).” NCT02200445 ↗ “IL-2 at 6 million IU subcutaneously (SC) every other day” NCT03081780 ↗ “repeated administration of low-dose IL-2 (1MUI/day, sc)” NCT01988506 ↗ “The infusion is followed by a course of low-dose IL-2.” NCT01081223 ↗ “Systemic low-dose-interleukin-2 (IL-2) Administration” NCT00912418 ↗ “followed by the administration of aldesleukin (IL-2).” NCT03526185 ↗ “subcutaneous low dose IL-2, interferon-α or sunitinib” NCT00397345 ↗ “recombinant human interleukin 2 (aldesleukin; IL-2)” NCT00000986 ↗ “Aldesleukin (interleukin-2, IL-2) immunotherapy” NCT06530303 ↗ “interleukin-2 (also called IL-2 or aldesleukin)” NCT00038259 ↗ “recombinant interleukin-2 ( aldesleukin; IL-2 )” NCT00000680 ↗ “recombinant interleukin-2 (aldesleukin; IL-2)” NCT00001005 ↗ “IL-2 (Interleukin-2) is an essential cytokine” NCT06108596 ↗ “high dose interleukin-2 (IL-2; aldesleukin)” NCT02390739 ↗ “low dose IL-2 (interleukin 2) (aldesleukin)” NCT03007238 ↗ “IL-2 (2 × 105 IU/m2) injections 3 times/wk” PMID 36038262 ↗ Aug 2022 “fixed dose regimen of interleukin (IL)-2” PMID 12473581 ↗ Dec 2002 “along with high-dose aldesleukin (IL-2)” NCT01993719 ↗ “Human Interleukin-2 (IL-2) (Proleukin)” NCT05821686 ↗ “subcutaneous interleukin-2 (IL-2)” NCT05080790 ↗ “Aldesleukin (IL-2) administration” NCT05155033 ↗ “low-dose IL-2 or IL-15 agonist” NCT07510828 ↗ “IL-2 (ILT-101) Sub-cutaneous” NCT04133233 ↗ “interleukin-2 (IL-2) therapy” NCT00001354 ↗ “supported with low dose IL-2” NCT02870244 ↗ “Aldesleukin (IL2), 3x10 IU” NCT01884688 ↗ “Interleukin-2 [IL-2]” NCT05975554 ↗ “interleukin-2 (IL-2)” NCT00000889 ↗ “interleukin-2 (IL-2)” NCT00136448 ↗ “Interleukin-2 [IL-2]” NCT04241601 ↗ “Interleukin-2 (IL-2)” NCT00006022 ↗ “Interleukin-2 (IL-2)” NCT05810792 ↗ “Interleukin-2 (IL-2)” NCT01355562 ↗ “Interleukin-2 (IL-2)” NCT06971913 ↗ “Interleukin-2 (IL-2)” NCT00113282 ↗ “Interleukin-2 (IL-2)” NCT00176761 ↗ “interleukin-2 (IL-2)” NCT03991741 ↗ “Aldesleukin (IL-2)” NCT05194735 ↗ “IL-2 (Aldesleukin)” NCT07651319 ↗ “Aldesleukin (IL-2)” NCT00138229 ↗ “IL-2 (Proleukin®)” NCT03040401 ↗ “IL-2 as adjuvant” NCT02919644 ↗ “IL-2” NCT03044743 ↗ |
| Known as | IL-2LD | “The MIROCALS study tested the hypothesis that low-dose interleukin-2 (IL-2LD) improves survival and function in ALS.” PMID 40354799 ↗ May 20251“low-dose interleukin-2 (IL2LD) activates Tregs” PMID 37245191 ↗ May 2023 |
| Known as | IL2-fd | “In humans, the use of low doses of interleukin-2 (IL2-fd) (ILT-101) leads to activation and selective expansion of Tregs” NCT07589842 ↗ |
| Known as | ILT-101 | “ILT-101: 1MIU/day in a volume of 1 ml; subcutaneous injection every day during 5 consecutive days and then every week between Day 63 and Day 354.” NCT05153070 ↗ |
| Known as | Inteleukin-2 | “Biological: Inteleukin-2” NCT00277758 ↗ |
| Known as | Interferon-gamma (IFN-γ) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03112590 ↗ |
| Known as | Interleukin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00089453 ↗ |
| Known as | Interleukin-2 | “The investigators hypothesize that ex vivo expanded human autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cells (Polyclonal Tregs) plus Interleukin-2 (IL-2) administered...” NCT02772679 ↗269“This phase II trial studies efficacy of extracorporeal photopheresis and low dose aldesleukin (interleukin-2) in treating patients with chronic graft-versus-host disease...” NCT03007238 ↗ “To evaluate the short-term effects of administering zidovudine ( AZT ) at the same time with increasing doses of aldesleukin ( interleukin-2; IL-2 ) in patients with persistent...” NCT00000728 ↗ “These cells kill tumor cells in a non-MHC restricted manner, do not induce graft-versus-host disease (GVHD), and can be generated by stimulation with zoledronic acid (ZA) in...” PMID 38165016 ↗ Jan 2024 “subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks...” NCT01862120 ↗ “Each patients will receive four cycles of subcutaneous Proleukin (Interleukin-2, IL-2) (Week-1; 1.5 million IU (MIU)/d from Day-1 to Day-5, Week-3, -6, -9; 3MIU/d from Day-1 to...” NCT02714959 ↗ “The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in...” NCT00110812 ↗ “Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal...” PMID 19622576 ↗ Jul 2009 “Interleukin-2 (IL-2) plays a critical role in immune regulation, promoting T-cell growth and differentiation and enhancing cytotoxic T lymphocyte (CTL) and natural killer (NK)...” NCT06577194 ↗ “Intraperitoneal chemotherapy (fluorouracil + nab-paclitaxel + cisplatin + interleukin-2) PLUS systemic chemotherapy (SOX regimen: oxaliplatin + tegafur-gimeracil-oteracil potassium)” NCT07034742 ↗ “Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.” NCT03312335 ↗ “Administration of interleukin-2 (also known as aldesleukin or IL-2), a naturally occurring cytokine, has been proposed as a way to maintain the number of CD8 cells.” NCT00110578 ↗ “Interleukin-2 (IL-2) treatment, a type of immunotherapy, uses the body's immune system to slow or stop the spread of cancer cells to other parts of the body.” NCT00352885 ↗ “Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing).” NCT04165967 ↗ “The aim of this study was to assess efficacy and safety of adjuvant treatment with low doses of interleukin-2 (IL-2)+interferon-α (IFN-α) in operable RCC.” PMID 25304727 ↗ Nov 2014 “Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC)” NCT00609401 ↗ “Eligible subjects will receive injection of C-TIL052A (Autologous Tumor Infiltrating Lymphocytes, TIL) and interleukin 2 (IL-2) after lymphodepletion.” NCT05475847 ↗ “A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma” NCT01683188 ↗ “Interleukin-2 (IL-2) is a standard treatment for cancer, which means that it can be received even if one chooses not to participate in this study.” NCT00325507 ↗ “an infusion of NK cells, supported by interleukin 2 (IL-2) or IL-15, could decrease virus-producing cells in the lymphatic tissues.” PMID 38207119 ↗ May 2024 “NK cells will be intravenously infused to the patient for 2 days, with following subcutaneously injection of Interleukin-2.” NCT04209712 ↗ “immunotherapy with subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment” NCT00003991 ↗ “Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer” NCT02306954 ↗ “Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.” NCT00912418 ↗ “After cell infusion, patients will receive low-dose interleukin-2 therapy which is an approved drug to treat melanoma.” NCT01883323 ↗ “Interleukin-2 (IL-2) is a promising candidate drug, synergizing with PD-1 blockade to exert anti-cancer effects.” NCT06394791 ↗ “Drug1 : Fludarabine + Cyclophosphamide Drug2 :Interleukin 2 Drug3 :KRAS-specific Autologous TCR-T cell injection” NCT06767046 ↗ “Administration of up to six doses of intravenous interleukin-2 (IL-2) following lifileucel (AMTAGVI) infusion.” NCT07700121 ↗ “Interleukin-2, abbreviated as IL2, is a naturally produced growth hormone for the immune cells in our body.” NCT00283829 ↗ “granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon alpha (IFN) and interleukin-2 (IL-2)” NCT01176552 ↗ “Interleukin 2 (IL-2, aldesleukin) was discovered as a T cell growth factor more than 30 years ago.” NCT01445561 ↗ “Adjuvant, Combined Interleukin 2 (Proleukin) and DTIC (Dacarbazine) in High-risk Melanoma Patients” NCT00553618 ↗ “To see if very low doses of Interleukin-2 after a partially matched transplantation prevent GVHD.” NCT02226861 ↗ “Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.” NCT00311467 ↗ “Subcutaneously Administered Aldesleukin ( Interleukin-2; IL-2 ) Therapy in HIV-Infected Patients” NCT00000821 ↗ “subcutaneous interleukin-2 (aldesleukin; IL-2) in patients with myelodysplastic syndrome (MDS)” NCT00002746 ↗ “Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.” NCT02997150 ↗ “comprising interleukin-2 (IL-2) IV continuously over days 1-5, 15-19, 43-47, and 57-61” NCT00416871 ↗ “IL-2 (interleukin-2, a protein found in the blood that helps boost the immune system)” NCT00006291 ↗ “Interleukin-2 may stimulate a person's white blood cells to kill solid tumor cells.” NCT00002994 ↗ “day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.” NCT02845999 ↗ “Low dose Interleukin-2 (Aldesleukin) administration to expand Regulatory T cells” NCT05821153 ↗ “Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.” NCT00277017 ↗ “combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil” PMID 20153039 ↗ Feb 2010 “From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.” NCT00197912 ↗ “from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.” NCT00197860 ↗ “infusions of a growth factor-like substance called interleukin-2 (IL-2)” NCT00080353 ↗ “Interleukin-2 (IL-2) 3 MIU/m2/day will be given by continuous infusion” NCT02169609 ↗ “Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.” NCT01462903 ↗ “Patient will be treated with low dose of Interleukin 2 (PROLEUKIN ®)” NCT05468073 ↗ “short course of subcutaneous interleukin-2 (IL-2) administered” NCT03081780 ↗ “Interleukin-2 2 million units/time on Days 4, 11, 18, and 25” NCT05497739 ↗ “Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).” NCT02200445 ↗ “IL2 (Interleukin 2; low dose injected subcutaneously)” NCT00200577 ↗ “supplemental human recombinant interleukin 2 (IL-2)” NCT06255028 ↗ “Cyclophosphamide, Fludarabine, Interleukin-2, Mesna” NCT00640796 ↗ “Aldesleukin (interleukin-2, IL-2) immunotherapy” NCT06530303 ↗ “interleukin-2 (also called IL-2 or aldesleukin)” NCT00038259 ↗ “recombinant interleukin-2 (aldesleukin; IL-2)” NCT00001005 ↗ “High Dose Aldesleukin (Interleukin-2)” NCT01856023 ↗ “Interleukin-2 (aldesleukin)” NCT00910650 ↗ “Interleukin-2 (ILT-101)” NCT02424396 ↗ “Drug 2: Interleukin-2” NCT06358053 ↗ “Interleukin-2 (IL-2)” NCT00001832 ↗ “Interleukin-2 (IL-2)” NCT00913913 ↗ “interleukin-2 (IL-2)” NCT00000889 ↗ “IL-2 (interleukin-2)” NCT00091611 ↗ “IL-2 (interleukin 2)” NCT02949492 ↗ “Interleukin-2 (IL-2)” NCT00006022 ↗ “IL-2 (interleukin 2)” NCT07105176 ↗ “Drug: interleukin-2” NCT02845999 ↗ “Interleukin 2 (IL2)” NCT04729543 ↗ “interleukin-2” NCT03970954 ↗ |
| Known as | Interleukin-2 (aldesleukin) | “Interleukin-2 (aldesleukin)” NCT00910650 ↗ |
| Known as | Interleukin-2 (IL-2) | “Interleukin-2 (IL-2)” NCT02169609 ↗ |
| Known as | Interleukin-2, Proleukin, Chiron B.V. | “Interleukin-2, Proleukin®, Chiron B.V.” NCT00935558 ↗3“Interleukin-2, Proleukin®, Chiron B.V.” NCT00197912 ↗ “Interleukin-2, Proleukin®, Chiron B.V.” NCT00937625 ↗ “Interleukin-2, Proleukin®, Chiron B.V.” NCT00937300 ↗ |
| Known as | interleukin-2: IL-2, aldesleukin, Proleukin(R) | “interleukin-2: IL-2, aldesleukin, Proleukin(R)” NCT00640796 ↗ |
| Known as | interleukine-2 | “Phase I study of zoledronic acid combined with escalated doses of interleukine-2 for early in vivo generation of Vγ9Vδ2 T-cells after haploidentical stem cell transplant with...” PMID 38165016 ↗ Jan 2024 |
| Known as | L2-7001 | “Safety and Effectiveness of L2-7001 (Interleukin-2) in HIV-Positive Patients Receiving Anti-HIV Therapy” NCT00002449 ↗ |
| Known as | Ld-IL-2 | “AIMS/HYPOTHESIS: Low-dose IL-2 (ld-IL2) selectively activates and expands regulatory T cells (Tregs) and thus has the potential to skew the regulatory/effector T (Treg/Teff)...” PMID 32607749 ↗ Jul 20203“Low-dose interleukin 2 (Ld-IL2) has shown therapeutic effects in autoimmune diseases, particularly systemic lupus erythematosus (SLE), yet optimal dosage has not been...” PMID 42014401 ↗ Apr 2026 “Patients with T1D were treated with a single infusion of autologous polyclonal Tregs followed by one or two 5-day courses of recombinant human low-dose IL-2 (ld-IL-2).” PMID 34324441 ↗ Sep 2021 “Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer” NCT03039673 ↗ |
| Known as | low-dose IL-2 | “Efficacy and safety of low-dose IL-2 as an add-on therapy to riluzole” PMID 40354799 ↗ May 2025 |
| Known as | Low-dose interleukin 2 | “Low-dose interleukin 2 (Ld-IL2) has shown therapeutic effects in autoimmune diseases, particularly systemic lupus erythematosus (SLE), yet optimal dosage has not been...” PMID 42014401 ↗ Apr 2026 |
| Known as | PEG IL-2 | “polyethylene glycolated interleukin-2 (PEG IL-2)” NCT00001997 ↗ |
| Known as | Proleukin | “treatment group patients will be treated intralesionally with IL-2 (Proleukin (Aldesleukin), Novartis Pharmaceuticals Canada Inc.) at a dose of 500,000 International Units (IU)...” NCT03233828 ↗35“Aldesleukin (Proleukin; recombinant human IL-2), which is administered at high doses to activate the immune system in cancer immunotherapy, is now being repositioned to treat...” PMID 27727279 ↗ Oct 2016 “This study will assess the highest tolerable intratumoral dose of ipilimumab (Yervoy) in combination with IL-2 (Proleukin) in patients with unresectable stages III-IV melanoma...” NCT01672450 ↗ “Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.” NCT03312335 ↗ “IL-2 (Interleukin-2; Aldesleukin; Proleukin) administered daily as a single subcutaneous injection 0.30 MIU per meter squared body surface area for a duration of 4 weeks.” NCT02739412 ↗ “The TIL injections are systematically followed by subcutaneous injections of Proleukin® (IL-2) at a concentration of 6 million international unit (IU) per day for 5 days.” NCT03374839 ↗ “IL-2 (Proleukin) will be administered on Day 2 (within 24h after NK infusion), 4 and 6 as a subcutaneous dose of 5x105 UI/m2, following the label instructions.” NCT05385705 ↗ “Interleukin-2 (Proleukin): 125.000 IU/kg/day s.c. for maximum 12 days as inpatients with a 2 days break after the first 4-5 doses (maximum 10 days dosing).” NCT04165967 ↗ “A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3” NCT00000949 ↗ “immunotherapy with subcutaneous Maxamine (Histamine Dihydrochloride) Plus Proleukin (Interleukin-2) Versus No Treatment” NCT00003991 ↗ “recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:” NCT01840046 ↗ “low doses 2·4×106 IU/m2 rhIL-2 (Proleukin®) (Chiron Emeryville, CA, USA), injected s.c.” NCT06152367 ↗ “recombinant interleukin-2 (aldesleukin; Proleukin) administered subcutaneously” NCT00002107 ↗ “HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion” NCT01896271 ↗ “Abatacept Injection [Orencia] and Proleukin (aldesleukin)” NCT06307301 ↗ “Study drug: Interleukin-2 (aldesleukin, Proleukin, IL-2).” NCT04263831 ↗ “Proleukin (Aldesleukin) in Combination With Ganciclovir” NCT00002321 ↗ “recombinant interleukin-2 (Proleukin, Aldesleukin)” NCT00040586 ↗ “Interleukin 2, 1MUI.= Proleukin®, RhIL-2” NCT01988506 ↗ “Human Interleukin-2 (IL-2) (Proleukin)” NCT05821686 ↗ “Interleukin-2, Proleukin®, Chiron B.V.” NCT00937300 ↗ “Interleukin-2 (Proleukin)” NCT00000889 ↗ “Drug: IL-2 (Proleukin)” NCT04389229 ↗ |
| Known as | Proleukin = Interleukin II | “Proleukin = Interleukin II” NCT00149162 ↗ |
| Known as | recombinant human IL-2 | “Aldesleukin (Proleukin; recombinant human IL-2), which is administered at high doses to activate the immune system in cancer immunotherapy, is now being repositioned to treat...” PMID 27727279 ↗ Oct 20163“Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.” NCT07011004 ↗ “subcutaneous recombinant human IL-2 following lymphodepleting chemotherapy.” NCT05218408 ↗ “Female NZB/W F1 mice received recombinant human IL-2 (3 × 104 IU/dose)” PMID 34094549 ↗ Jun 2021 |
| Known as | Recombinant Human Interleukin-2 | “recombinant human interleukin-2 in treating subjects with refractory cGVHD” NCT06920199 ↗6“recombinant human interleukin 2 (aldesleukin; IL-2)” NCT00000986 ↗ “recombinant human interleukin 2 (rhIL2) PROLEUKIN ®” NCT06152367 ↗ “Recombinant Human Interleukin-2” NCT04237987 ↗ “recombinant human interleukin-2” NCT00005576 ↗ “Recombinant Human Interleukin-2” NCT04062019 ↗ “Recombinant Human Interleukin-2” NCT05495321 ↗ |
| Known as | Recombinant Human Interleukin-2(1) for Injection | “Recombinant Human Interleukin-2(1) for Injection” NCT05631717 ↗ |
| Known as | recombinant human low-dose IL-2 | “Patients with T1D were treated with a single infusion of autologous polyclonal Tregs followed by one or two 5-day courses of recombinant human low-dose IL-2 (ld-IL-2).” PMID 34324441 ↗ Sep 2021 |
| Known as | Recombinant Interleukin-2 | “The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in...” NCT00110812 ↗4“recombinant interleukin-2 (Proleukin, Aldesleukin)” NCT00040586 ↗ “recombinant interleukin-2 ( aldesleukin; IL-2 )” NCT00000680 ↗ |
| Known as | Rh-Interleukin-2 | “8 Weeks SC Administration of Aldesleukin (Rh-Interleukin-2 [IL-2]) to 4 Weeks of IV Administration of Rituximab” NCT00100737 ↗ |
| Known as | rhIL-2 | “One million units of Recombinant Human Interleukin-2 (rhIL-2) was administered subcutaneously five days every week for 4 weeks and then once a week for 8 weeks.” NCT04062006 ↗7“Subjects will receive subcutaneous recombinant human IL-2 (rh-IL2) every other day x 6 doses beginning on day 0 via subcutaneous injection.” NCT07011004 ↗ “Human recombinant interleukin-2 (rhIL-2) is a biological signalling protein playing a key role in the regulation of the immune system.” NCT01862120 ↗ “Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks” NCT02569463 ↗ “One million units of Recombinant Human Interleukin-2 (rhIL-2) was administered subcutaneously every other day for 3 months.” NCT04237987 ↗ “One million units of Recombinant Human Interleukin-2 (rhIL-2) was administered subcutaneously every other day for 3 months.” NCT04062019 ↗ “recombinant human interleukin 2 (rhIL2) PROLEUKIN ®” NCT06152367 ↗ “Interleukin 2, 1MUI.= Proleukin®, RhIL-2” NCT01988506 ↗ |
| Known as | rIL-2 | “The purpose of this study is to determine the effect of short cycles of recombinant interleukin-2 (also known as rIL-2 or aldesleukin) given with or without anti-HIV drugs in...” NCT00110812 ↗4“A Study to Evaluate the Effects of Giving Proleukin (rIL-2) to HIV-Positive Patients With CD4 Counts Greater Than 300 Cells/mm3” NCT00000949 ↗ “humanized 3F8" (Hu3F8) when combined with interleukin-2 (rIL2) is safe for treating neuroblastoma and other cancers.” NCT01662804 ↗ “Recombinant interleukin-2 (rIL-2) therapy used with combination anti-HIV medication of choice.” NCT00004978 ↗ |
| Action | Restore | “Replacement of IL-2 at nontoxic doses” NCT00000820 ↗ |
| Modality | Protein / enzyme biologic | “recombinant interleukin-2 ( aldesleukin; IL-2 )” NCT00000680 ↗ |
| Route | Subcutaneous | “by Subcutaneous Injection” NCT00000820 ↗ |